These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208 [TBL] [Abstract][Full Text] [Related]
4. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Frey K; Kilbourn M; Robinson T Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358 [TBL] [Abstract][Full Text] [Related]
12. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Fricks-Gleason AN; German CL; Hoonakker AJ; Friend DM; Ganesh KK; Carver AS; Hanson GR; Fleckenstein AE; Keefe KA Synapse; 2016 Apr; 70(4):139-46. PubMed ID: 26799527 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Bourque M; Liu B; Dluzen DE; Di Paolo T Biochem Pharmacol; 2007 Nov; 74(9):1413-23. PubMed ID: 17825264 [TBL] [Abstract][Full Text] [Related]
14. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144 [TBL] [Abstract][Full Text] [Related]